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Incidence and outcomes after infolding or collapse
of thoracic stent grafts
Karthikeshwar Kasirajan, MD,a Michael D. Dake, MD,b Alan Lumsden, MD,c Joseph Bavaria, MD,d and
Michel S. Makaroun, MD,e Concord and Stanford, Calif; Houston, Tex; and Philadelphia and Pittsburgh, Pa
Objective: Device-related complications in the thoracic aorta are partly due to the unavoidable proximal angulation and
increased flow-related forces. The present study evaluated the incidence, predictors, and outcome of the complication of
infolding with the GORE TAG thoracic endoprosthesis (TAG device) to better understand the factors that might help
predict these events.
Methods: We reviewed all complaints reported to W. L. Gore and Associates (Flagstaff, Ariz) related to device infolding
after the use of the GORE TAG device on or before December 2008. Events related to device infolding were evaluated.
Reporting physicians and local company representatives were contacted, when necessary, to assemble all available
imaging, data, and outcomes related to these case reports. When available, computed tomography images were reviewed
to confirm aortic landing zone diameters, which were subsequently compared with the implanted device size.
Results: From 1998 through December 2008, device infolding was reported in 139 patients (mean age, 40  17 years;
73.4% men) from 33,289 device implants (reported incidence, 0.4%). Events were noted in implants for trauma (60%),
dissection (19%), aneurysm (10%), and other (9%) and unknown (2%) etiologies. In 77 patients with available imaging,
the average minimum aortic diameter was 21.4 4.4 mm. Themean device diameter was 28.5 3.5 mm, with an average
oversizing of nearly 33%. Of reported patients, 51% were asymptomatic, with the diagnosis being made on routine chest
imaging. Time to diagnosis was 76  222 days (median, 9.5 days). Only 16 patients received no intervention after the
diagnosis of device infolding, all of whom were asymptomatic. The other 123 patients underwent 135 interventions. Of
these, 30 patients (24%) underwent open surgical conversion and complete or partial endograft removal. The other
interventions included a variety of endovascular techniques, such as large balloon-expandable stent(s) in 40%, relining
with additional endograft(s) in 31%, and repeat ballooning in seven patients. Ten patients died after device infolding, all
after one or more attempts to repair the infolded device: five died of symptoms related to the infolding and five secondary
to the intervention undertaken to correct the device infolding.
Conclusions: TAG device infolding appears to be an infrequent event, primarily occurring in young trauma patients
secondary to excessive oversizing and severe proximal aortic angulation. However, there clearly exists a need for devices
that treat such patients. As a result, future device designs should consider the compression failure mode when being
designed in order to help prevent such events. ( J Vasc Surg 2012;55:652-8.)
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0Endovascular stent grafts are fast becoming the stan-
dard of care for all pathologies affecting the descending
thoracic aorta. This is clearly the result of their successful
application in the infrarenal aorta in combination with the
relatively high morbidity and mortality of open thoracic
surgical repair. However, similar to surgical outcomes,
endovascular repair of the thoracic aorta has proved to be
more challenging than that of the abdominal aorta, having
a greater frequency and variety of device-related complica-
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652ions such as device compression, invagination, misaligned
eployment, kinks, retrograde type A dissections, and aor-
ic perforation.1-3
The focus of this report is on device compression and
nvagination, herein collectively referred to as device infold-
ng. The objective of this report is to review device-infolding
vents with the GORE TAG Thoracic Endoprosthesis
W. L. Gore and Assoc, Flagstaff, Ariz) in an attempt to
etter understand the failure mechanisms and to examine
atient outcomes. We hope that such an understanding will
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Volume 55, Number 3 Kasirajan et al 653provide an improved ability to manage patients and con-
tribute to the design of future thoracic endografts that are
not susceptible to these failure modes.
METHODS
Device description. The GORE TAG device is a self-
expanding endoprosthesis constructed of an expanded
polytetrafluoroethylene graft bonded to a nitinol stent
frame, the sinusoidal stent pattern of which provides the
device with flexibility and kink resistance. Endoprosthesis
sizes range in diameter from 26 to 45 mm, with a corre-
sponding aortic inner diameter treatment range from 23 to
42 mm (oversizing range, 6%-22%).
Data collection. Data were collected from a review of
all complaints related to device infolding received by W. L.
Gore between the first device release in 1998 through
December 2008. The data compiled for all reported events
included information obtained from the reporting physi-
cian and local sales teams. In all cases, attempts were made
to collect all relevant patient information, including any
available imaging studies, reinterventions performed, and
any other patient follow-up data.
Definitions. For the purposes of this review, the term
device infolding is used to describe device compression as
well as device invagination. Although this data set does not
allow these event types to be analyzed separately, we believe
it may be important to provide definitions for the two
events. To this end, device compression (Fig 1, A) is
defined as failure of the device to maintain its intended
expanded diameter after implantation. Device invagination
(Fig 1, B) is defined as device infolding upon deployment
due to anatomic constraints.
In general, the primary difference between these two
events is mechanistic: device compression is the result of the
dynamic application of external forces on the device (eg,
blood flow), and device invagination is the result of an
anatomic restriction (eg, extreme oversizing). In cases such
as in the treatment of aortic dissection with a small distal
Fig 1. Radiographic appearance of (A) detrue lumen diameter, device invagination is anticipated due Oo the extreme oversizing. In this instance, it is expected
hat the invagination might resolve with the coverage and
ealing of the primary entry tear and depressurization of the
alse lumen.
Image evaluation. Available computed tomography
CT) images were evaluated by an independent reviewer to
ssess aortic diameter within the treated area. Diameters
ere measured at three regions of the proximal and distal
ortic neck: at the edge of the device and at 10 mm and 20
m from the end. Measured vessel diameters were com-
ared with the implanted device diameter to determine the
mount of device oversizing. Sizing was considered off-
abel if any of these six diameters was outside the prescribed
anges for the respective device size.
ESULTS
Patient population and device oversizing. During a
eriod of 10 years (1998 to 2008) approximately 33,289
AG devices were implanted worldwide. During this time,
39 reports of device infolding were reported to W. L.
ore, for a 0.4% incidence rate. Of these events, 60.4%
ere noted in trauma patients. Other etiologies included
issection in 18.7%, aneurysms in 10.1%, others in 9.4%,
nd unknown in 1.4%. Patients were a mean age of 40 17
ears overall, with trauma patients aged 31  12 years
ompared with 51  16 years for all others.
The most common device diameter was 26 mm in 65
atients (47%), followed by the 28-mm device in 38 (27%;
ig 2). Imaging studies were available for 77 patients
55%), in which the average minimum aortic diameter at
he stented segment was 21.4  4.4 mm and the mean
evice diameter implanted was 28.5 3.5 mm, resulting in
n average oversizing of approximately 33%. The mean
ortic diameter for trauma patients was 19.7  2.7 mm,
ith a mean device diameter of 26.8 mm, for an overall
verage of 36% oversizing. In the dissection population, the
ean aortic diameter was 26.2 5mm, with a mean device
iameter of 31.6  3.5 mm, for a 20% device oversizing.
invagination and (B) device compression.nly four image sets were available for review for aneurysm
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March 2012654 Kasirajan et alpatients: in the first patient, a 31-mm-diameter device was
inserted in a 22-mm neck (41% oversizing), the second
patient had placement of a 34-mmdevice in a 23-mm aortic
neck (48% oversizing), the third patient had placement of a
26-mm device in a 25-mm neck (4% oversizing), and the
last patient had placement of a 37-mm device in a 38-mm
aortic diameter (3% oversizing).
Patient presentation. The median time from initial
treatment to diagnosis of invagination or compression was
9.5 days (range, 0-2190 days; average, 76  222 days).
Approximately 75% of all compressions were diagnosed1
month of the initial treatment (Fig 3). Overall, only 42
patients (30%) were confirmed to have had symptoms
related to the event, compared with 71 (51%) diagnosed
with device infolding on routine follow-up imaging. Pre-
senting symptom data were unavailable for 26 patients. The
most common presenting symptoms were hypertension,
back or chest pain, oliguria, claudication, and paraplegia.
Secondary interventions and patient outcomes. Of
the 139 device infolding events, 10 patients (7%) were
reported to have died, each after undergoing one or more
Fig 2. Device sizes associated with infolding events.surgical or endovascular interventions in an attempt to iepair the infolded endograft. Interventions that resulted in
he re-expansion or removal of the infolded endograft were
onsidered successful, regardless of the eventual patient
utcome. In all, 135 reinterventions were performed in
23 patients (Table I), and 16 asymptomatic patients had
o intervention.
The most common interventions were implantation of
balloon-expandable stent (50 patients), implantation of
n additional self-expanding endograft (39 patients), and
onversion to conventional open surgery (30 patients). In
ome cases, a balloon-expandable stent and an endograft
ere both implanted. These patients were captured within
he balloon-expandable stent group. Overall, 108 of 135
otal interventions (80% of reinterventions) were successful
n re-expanding or removing the infolded endograft.
An additional 15 patients reportedly underwent inter-
ention to attempt to resolve the device infolding. Of these,
ollow-up information was unavailable for six patients. In-
erventions performed in the remaining nine patients were
eported to be unsuccessful in resolving the device infold-
ng, six of whom ultimately died. The remaining four
atient deaths were reported to have occurred despite
uccessful device re-expansion or removal. Among the
eath reports available, two were related to cerebrovascular
vents, two secondary to delayed cardiac events, one sec-
ndary to a flare perforation in a patient with dissection,
nd one due to multisystem organ failure secondary to
ortic occlusion.
ISCUSSION
The outcomes presented in this large series of patients
ed us to the creation of the event classification system and
ecommended treatment plan proposed in Table II, which
s based on the type of device infolding and its anatomic
ocation. These recommendations should be considered
long with the understanding that clinical studies that
epend on voluntary reports of device malfunction to the
evice manufacturer, such as this one, may represent an
nder-reporting of the true incidence rate. In the case of
his report, however, an aggressive effort was made by the
ompany to have local sales representatives query physicians
mplanting the device on any unreported malfunction.
ence, we believe these data are highly representative of
he real-world incidence and outcomes.
Another shortcoming of the study was the absence of
maging studies for all patients. The ideal situation would
ave been to have access to all CT images before and after
mplant along with intraoperative studies. Nevertheless, it
ppears from the available data that most of the complica-
ions secondary to this relatively infrequent event occurred
hen devices were used “off-label,” particularly in the
etting of dramatic device oversizing and especially in the
rauma patient population. This finding appears somewhat
ontrary to the average oversizing of 20% reported for the
issection patient population. However, because device
election in the dissection population is typically based
olely on the proximal aortic diameter, there is often signif-
cant distal oversizing due to the pronounced reduction in
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entry tear of the dissection. On the basis of this anatomic
configuration, we believe that the TAG device, when used
for treatment of dissections, needs to be minimally over-
sized, probably not more than 10%.
In addition to the high frequency of excessive device
oversizing, other factors might predispose devices to com-
pression events.4-6 One such factor is the characteristic
tight radius of curvature of the aortic arch in young patients
compared with that of aneurysmal patients, in whom the
Fig 3. Length of time between device im
Table I. Treatment outcomes
Technique
Primary reintervention outcome
Total Success Failure Unknown Death
No. (%) No. (%) No. (%) No. (%) No. (%)
BX stent 49 (40) 42 (86) 5 (10) 2 (4) 3 (6)
Stent graft 38 (31) 30 (79) 8 (21) 0 (0) 2 (5)
Conversion 21 (17) 18 (86) 0 (0) 3 (14) 1 (5)
Ballooning 8 (7) 4 (50) 4 (50) 0 (0) 1 (13)
Other 7 (6) 4 (57) 2 (29) 1 (14) 1 (14)
Total 123 (100) 98 (80) 19 (15) 6 (5) 8 (7)
Secondary reintervention outcome
BX stent 1 (8) 1 (100) 0 (0) 0 (0) 0 (0)
Stent graft 1 (8) 1 (100) 0 (0) 0 (0) 0 (0)
Conversion 9 (75) 8 (89) 1 (11) 0 (0) 1 (11)
Ballooning 1 (8) 0 (0) 1 (100) 0 (0) 1 (100)
Other 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Total 12 (100) 10 (83) 2 (17) 0 (0) 2 (17)
BX, Balloon-expandable stent.arch is typically elongated. This aggressive angulation can desult in poor apposition of the device to the vessel wall
long the inner curvature of aortic arch, termed “bird
eaking” (Fig 4). Although this result is not desirable
ecause of the loss of some seal length within the aortic
eck and because it exposes the abluminal device surface to
he force of the bloodstream, this effect appears to be
enign in most patients. When the device is excessively
versized, however, the risk this represents may be ele-
ated, particularly in young patients with high cardiac
utput.
The inverse relationship between cardiac output and
ge has been established in numerous publications.7-9 In-
erent in this relationship is that a device placed into the
orta of a young patient will be subjected to greater flow-
elated forces than one placed in an elderly patient. This
henomenon is further compounded by the small aortic
t and diagnosis of infolding by etiology.
able II. Event classification system and recommended
reatment plan
lassification Description
Proposed treatment
options
ype Ia Proximal invagination Reline and balloon
expansion
ype Ib Distal invagination Reline or observe if no
flow limitation
ype IIa Proximal compression Explant or reline
ype IIb Distal compression Has not been reported as
an isolated event
ype III Complete graft
compression
Open surgical conversioniameters of most trauma patients, which only serves to
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the resultant force.10 If this force exceeds that being
exerted outward by the implanted stent graft, compres-
sion of the device to the outer curvature of the aorta will
occur.11
In the event of excessive bird-beaking, consideration
should be given to relining the device with a similar diam-
eter and length TAG (Fig 5) or possibly placing a Palmaz
stent (Videos 1 and 2, online only) to achieve a better
apposition of the graft to the aortic inner wall. Bird-beaking
as an isolated event was not reported as an adverse event,
and the true incidence of this remains unknown. However,
we believe that bird-beaking as an isolated event may not
necessarily result in device compression, because this has
not occurred with a high incidence in patients with degen-
erative aneurysms, many of whom may have had the bird-
beaking phenomenon.
Treatment recommendations are provided in Table
II. Balloon dilatation as a stand-alone reintervention has
a 50% failure rate and should be avoided. The use of
balloon-expandable stents and relining with a second
endograft of the same diameter were equally successful,
at 86% and 79%, respectively. Open surgical conversion,
although highly invasive, had a very high success of 86%
with a low mortality rate of 5%. In the event of total
device compression from the proximal to distal end, this
would probably be the best intervention in patients who
are surgical candidates, because explant analysis has dem-
onstrated significant material fatigue in patients with
total device compression. In addition to the above-
Fig 4. Image shows inadequate apposition of the graft to the
inner aortic wall, referred to as bird-beaking; in this case, bird-
beaking was associated with significant device undersizing
proximally.mentioned factors that may predispose to device com- tression or infolding, low radial force, material fatigue,
nd covered flares may predispose to these events.
Device infolding has been reported with most com-
ercial devices and is often demonstrated to occur most
ften when used outside of the device instructions for
se (IFU), typically due to improper device sizing.12-16
his can occur as a result of inadequate device opening
elated to anatomic constraints, defined here as device
nvagination (Fig 1, A), or may also occur in a delayed
ashion that most commonly presents as a collapse
gainst the aortic wall, defined as device compression
Fig 1, B). Of the two event types, most of the clinical
nterest in recent years has been focused on device com-
ression because it appears to be the most common,
ypically occurs postprocedurally, and has been associ-
ted with the most severe clinical sequelae.
The TAG device is currently approved for treatment of
egenerative aneurysms with recommendations of 10% to
0% oversizing compared with the inner lumen of the
ative aorta. It is important to understand that the TAG
evice was the first to bemarketed in the United States, and
he smallest available size was 26 mm. Because this was the
nly U.S. Food and Drug Administration–approved device
vailable for nearly 3 years, physicians were forced to use
his for trauma patients, who have an average native aortic
iameter of 19.7 mm, resulting in the significant oversiz-
ng. The availability of other smaller-diameter devices and
he Conformable TAGwill likely eliminate the need for this
ramatic oversizing.
Only 12 patients (8.6%) in this study group underwent
AG device implantation for a degenerative aneurysm of
he descending thoracic aorta. Of these, it is unfortunate
ig 5. Relining with a same-sized TAG device to overcome the
ird-beaking phenomenon.hat CT scans for only four patients were available for
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sizing in all cases was not done as specified by the IFU,
highlighting the importance of sizing according to the
device IFU.
CONCLUSIONS
Current endovascular stent grafts, including the GORE
TAG device, were designed for the aneurysmal patient
population and, as a result, are at times not capable of
withstanding the forces applied when used in young trauma
patients. The next-generation thoracic stent grafts should
include features that allow for their broad application to
etiologies other than aneurysms such as trauma and dissec-
tion. These features include greater radial force, better
conformability to the inner curvature of acutely angulated
aortic arches, greater tolerance for device oversizing, and
smaller device diameters.17
One such device is the GORE Conformable TAG
Thoracic Endoprosthesis, which is currently available in
Europe and in clinical trials in the United States. This
device has been designed to have improved flexibility, with
more generous oversizing windows of between 6% and 33%
per device and includes both tapered and smaller device
diameters that are designed to treat aortas with inner diam-
eters as small as 16 mm (Fig 6). The expanded oversizing
ranges also afford a greater amount of flexibility in case
planning and device selection, which in many instances
allows for two or three different device diameters to be used
within the IFU for a given aortic diameter. The proximal
and distal ends of the device have also been redesigned,
with the removal of the flares and the addition of a short
length of uncovered stent apices on the device’s proximal
end. At the time of this publication, more than 2000 of
these devices have been implanted worldwide, with no
Fig 6. The expansion of the device oversizing range
flexibility in case planning and use in more tapered anatoreported incidences of device infolding or compressionespite its application in patients with traumatic transection
nd aortic dissection.
Within the United States, the performance of the
ext-generation Conformable GORE TAG device is be-
ng studied in three separate clinical trials for application
n aneurysm, trauma, and acute complicated type B
issection patients. Until this device and other next-
eneration devices become available with clinical data for
se in diverse patient populations, caution should be
xercised when using thoracic aortic stent grafts for
off-label” indications.
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Dr Roy K. Greenberg (Cleveland, Ohio). With respect to
your discussion on incidents, were they calculated on a per-device
basis or a per-patient basis?
Dr Karthikeshwar Kasirajan. Per-device basis. We had no
way of calculating it per patient; because we could account for how
many devices were implanted during the study period, but we did
not have data on howmany patients actually received these devices.
We also did that because some patients had two devices and
you could have an invagination on the second or the distal device.
So, it was more of a per-device event and not a per-patient event.
Dr Greenberg. I found the data you presented really interest-
ing with respect to the etiology and the timing in terms of the
occurrence, but the incidence is still a troubling thing because only
30% of the patients are symptomatic. We really don’t know what
the incidence is; we just know what you’ve told us in terms of the
timing, which is very helpful.
Dr Kasirajan. That’s right. So, if patients don’t come forDr Piergiorgio Cao (Rome, Italy). It seems that the majority
f your failures were due to excessive oversizing. Can you give us
ome insight about the fraction of patients with this problem due
o excessive oversizing versus patients with the bird beak effect that
an be improved with the new c-TAG?
Dr Kasirajan. In all patients on whom we have imaging
tudies, at least which were provided to us, all of them were out of
he instructions for use for their sizing. This event was most
ommonly seen in trauma patients and dissections; the oversizing
n trauma patients was 36% and in dissections, it was 20%. But, you
re now talking about oversizing to the proximal neck, so if you
ake a dissection patient, typically there is a dramatic oversizing in
he true lumen distally. So, all of them were oversized beyond the
nstructions for use, which is 20%. We didn’t have any isolated
ompression, just related bird-beaking events.
And currently, the c-TAG has been approved in Europe and
hey have close to 2500 implants with no compression events
eported to date. So, I do think it’s a matter of oversizing more
han anything else as the causation.
